Retatrutide

Overview

Retatrutide is a 39-amino acid modified peptide that functions as a triple agonist at the GIPR, GLP-1R, and GCGR. Its design incorporates multiple structural modifications — including alpha-aminoisobutyric acid (Aib) substitutions for protease resistance and a C20 fatty diacid via a γGlu-miniPEG linker attached to a lysine residue — which extend its plasma half-life and support once-weekly dosing in clinical research settings. This three-receptor pharmacological profile distinguishes it from dual agonists (GIPR/GLP-1R) and single agonists (GLP-1R), and has made it a subject of investigation in studies examining the combined metabolic contributions of each receptor pathway.

Research into Retatrutide has examined the pharmacological consequences of simultaneous triple receptor activation, with studies reporting effects on energy intake signaling, gastric emptying, glucose-stimulated insulin secretion, and adipose tissue dynamics. Clinical investigations have also examined secondary cardiovascular and glycemic parameters in research populations. Its triple-mechanism profile has been studied as a distinct pharmacological model for examining metabolic receptor biology across multiple interconnected systems.

Chemical Profile

Download Certificate of Analysis (COA)

Research Findings

Triple Receptor Pharmacology Research

Retatrutide has been studied as a simultaneous agonist at the GIPR, GLP-1R, and GCGR. Research has examined how concurrent activation of all three receptor systems compares to single- and dual-receptor pharmacological models, with preclinical studies characterizing receptor binding affinity, downstream cAMP signaling, and functional potency at each target.

GLP-1R activation has been examined in the context of glucose-stimulated insulin secretion and gastric emptying modulation. GIPR activation has been investigated for its role in nutrient-stimulated insulin release and its interactions with GLP-1R-mediated pathways. GCGR agonism has been studied for its effects on hepatic glucose output and energy expenditure pathways in experimental models. The structural modifications — Aib substitutions and fatty acid conjugation — have been examined for their contributions to protease resistance and pharmacokinetic half-life in pharmacology research settings.

Metabolic and Body Composition Research

Clinical research has examined Retatrutide's effects on body composition parameters in metabolically characterized research populations, with observations on body weight measures and adipose tissue distribution reported across clinical study settings. Research has investigated the contributions of each receptor pathway to the compound's metabolic profile, with GCGR agonism examined specifically for its proposed role in increasing energy expenditure relative to single or dual agonist comparators studied in experimental settings. Secondary metabolic parameters examined alongside body composition data have included circulating lipid fractions, liver fat parameters, and waist circumference measurements in clinical research populations.

Glycemic Parameter and Insulin Research

Clinical research examining Retatrutide has reported secondary observations on glycemic parameters including fasting glucose and HbA1c measurements in research populations. GLP-1R and GIPR activation both contribute to glucose-stimulated insulin secretion through distinct but complementary intracellular signaling cascades, and research has examined how Retatrutide's dual engagement of these pathways influences insulin secretion dynamics relative to individual receptor activation. Preclinical models have also investigated GCGR-mediated effects on hepatic glucose production as a third component of the compound's glycemic research profile. These glycemic observations have been examined as secondary endpoints in clinical studies investigating metabolic parameters in defined research populations.

Areas of Research

• GIP, GLP-1, and glucagon receptor pharmacology studies

• Triple receptor agonism and multi-pathway metabolic signaling research

• Body composition and adipose tissue parameter research

• Glycemic parameter and insulin secretion studies

• Hepatic glucose metabolism and energy expenditure research

• Lipid and cardiovascular metabolic parameter studies

Research Use Only: This product is sold exclusively for laboratory and scientific research. It is not approved for human or veterinary use or consumption.

Disclaimer: All products distributed by Resolve Peptides are supplied exclusively for controlled laboratory and scientific research. They are not drugs, supplements, or therapies, and have not been approved by the FDA or any regulatory authority for human or veterinary use. These products are not intended for human or veterinary administration. Regulatory status of research peptides is subject to change; it is the responsibility of the researcher to verify current applicable regulations in their jurisdiction prior to purchase. Any references to biological effects are based solely on experimental and preclinical data.